RISK FACTORS OF MULTIDRUG RESISTANT PATHOGENS INDUCED INFECTION IN SEVERE ACUTE Pancreatitis

Xina Li,* Le Li,† Lu Liu,* Yingying Hu,* Shuang Zhao,* Jialiang Sun,* Gang Wang,† and Xin Hai*

*Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, Harbin, China; and
†Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China

ABSTRACT—Purpose: A retrospective study was first performed to assess the multidrug resistant (MDR) pathogen in severe acute pancreatitis (SAP) patients who were treated using the step-up approach. We aim to assess the risk factors between MDR pathogen and potential covariates in SAP patients. Methods: The clinical data of 51 SAP patients who were treated from June, 2013 to December, 2016 were retrospectively collected. A total of 23 patients in the MDR group and 28 patients in the non-MDR group were reviewed. The risk factors for MDR pathogen-induced infections in SAP patients were analyzed. Results: Hyperlipidemia was the leading cause of SAP in our study. The mean duration of hospital stay was significantly longer in the patients with MDR pathogen infections (P = 0.0135). The hospitalization expenses of MDR group were much higher than those in non-MDR group. The mortality of MDR group (56.5%) was higher than that in non-MDR group (28.6%) (P = 0.0436). Gram-negative isolates (63.8%) were commonly detected in SAP patients. Acinetobacter baumannii was the most common MDR pathogens. Systemic disease (P = 0.0156), initial use of carbapenem (P = 0.0438), and open necrosectomy (P = 0.0002) were the potential risk factors for MDR pathogen-induced infections in SAP. Furthermore, the logistic regression analysis revealed that open necrosectomy was the independent variable for MDR infections (OR: 15.6, 95% CI: 2.951–82.469, P = 0.0012). Conclusions: MDR pathogen-induced infections were common in SAP patients and Acinetobacter baumannii was the main pathogen. Meanwhile, open necrosectomy was the independent risk factor for the infection of MDR pathogen.

KEYWORDS—Acinetobacter baumannii, multidrug resistant, open necrosectomy, pathogen, severe acute pancreatitis

INTRODUCTION

Acute pancreatitis is a commonly encountered emergency disease that requires immediate hospital admission. In most cases, acute pancreatitis represents a mild, self-limited disease. However, in 15% to 25% severe acute pancreatitis (SAP) develops, manifests with pancreatic parenchymal and/or peri-pancreatic tissue necrosis. Despite the great progress in the current therapies, the mortality rate is up to 30% to 70% (2). The clinical course of SAP is divided into two phases, an early inflammatory phase (lasts 2 weeks from the onset) and a late phase (after the first 2 weeks). Nevertheless, septic complications are the main cause of death in the late phase (3).

Adequate antibiotic therapy is critical to improve the clinical outcomes of patients with life-threatening infections. However, the continuous and misuse of antibiotics has developed a strong selective pressure on microorganisms, favoring the emergence of resistant strains (4). Recently, several studies have revealed that the incidence of infections caused by multidrug resistant (MDR) pathogen was increasing and the mortality associated with MDR was high in SAP (5). In addition, MDR pathogen infection plays a vital role in prolonged hospital and intensive care unit (ICU) stay (6). MDR pathogen infection is normal and difficult to treat in the SAP. The most common last resort antibiotics in the treatment of MDR pathogen infection were polymyxins and tigecycline. However, polymyxins are uncommon in China and the minimum inhibitory concentration value of tigecycline against bacterial is gradually increasing, which reduced the sensitivity of tigecycline (7). Therefore, better methods for the prevention and optimal treatment of MDR infection are essential and could improve the outcomes of SAP patients.

Previous studies have demonstrated that MDR pathogen colonization or infection, ICU admission, invasive procedures, age, systemic disease, and early use of broad-spectrum antibiotics are the crucial risk factors for MDR pathogen infections in patients with liver cirrhosis, hemodialysis-associated pneumonia, etc. (8–12). Lee et al. (13) found the high incidence of MDR bacterial infections in transferred SAP patients. However, the MDR pathogen infection and their clinical effects have been rarely reported in SAP patients especially in China. A minimally invasive step-up approach or open necrosectomy are both considerable strategies for the treatment of SAP. Our previous studies indicated that open pancreatic necrosectomy increases...
surgical trauma for patients, and step-up approach significantly reduces the cost, shortens the hospital stay, and improves the prognosis in SAP. But, the effect of different treatments for MDR pathogen infection is unclear. Thus, this retrospective study is performed to assess the MDR pathogen in SAP patients who were treated with step-up approach. We aim to assess the risk factors between MDR pathogen and potential covariates in SAP patients.

PATIENTS AND METHODS

Subjects
Evaluation of bacterial and fungal infections in SAP patients who were diagnosed between June, 2013 and December, 2016 at The First Affiliated Hospital of Harbin Medical University was retrospectively performed. This study was approved by the First Affiliated Hospital Institutional Review Board. One hundred sixteen patients were included from our database, and the diagnostic criteria of SAP were based on the revised 2012 Atlanta classification (14). To identify the SAP-induced infection, all the clinical features of culture and the corresponding files were reviewed by two infectious disease pharmacists and two professional pancreatic surgeons.

Treatments and culture
In our study, all the SAP patients received oral intake, pain relief, nutritional support and restoring fluid and electrolyte losses intravenously according to the guideline (15). Intravenous antibiotics were used for all the patients for either prophylactic or therapeutic purpose. Isolation of organism was defined as a positive culture obtained from blood, fine-needle aspiration, the first drainage of the percutaneous procedure, or intraoperative fluid. Isolated organisms were tested for antimicrobial susceptibility through minimum inhibitory concentration testing using the VITEK2 compact system (bioMerieux Inc, Hazelwood, Mo) or K-B method (Thermo Fisher Oxoid) according to the recommendations of the Clinical and Laboratory Standards Institute (16).

MDR organism definition
MDR pathogen was defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories. MDR includes extensive drug resistance (non-susceptibility to at least one agent in all but two or fewer antimicrobial categories) and pan drug resistance (non-susceptibility to all agents in all antimicrobial categories). Methicillin-resistant Staphylococcus aureus, Vancomycin-resistant Enterococcus, Carbapenem-resistant Enterobacteriaceae, MDR-Acinetobacter baumannii, and MDR-Pseudomonas aeruginosa were defined as healthcare-associated infections and prone to multidrug resistance (17,18).

Statistical analysis
The risk factors for MDR pathogen-induced infections in SAP patients were analyzed, including systemic disease (diabetes, hypertension, COPD, chronic renal insufficiency), invasive procedures (central venous catheterization, mechanical ventilation, urinary catheterization, and other invasive procedures), surgical intervention (open necrosectomy), recent antibiotic treatments (within 30 days of admission), transferred from other hospitals, admission to ICU and use of carbapenem before MDR pathogen. Numerical variables were summarized as the mean ± standard deviation (SD). Parametric and non-parametric analyses and multiple linear regression analysis were performed using the SPSS statistical package. Determination of the statistical differences in parameters between various groups was analyzed using either Student t test or Wilcoxon rank sum test. A P value of <0.05 was considered to be statistically significant.

RESULTS

Baseline characteristics
Microorganisms could not be found in 29 patients, 26 patients were excluded for death within the first 48 h from the onset of disease, six patients were excluded for giving up treatment in the first 24 h, and four patients were excluded for transferring to other hospitals. A total of 51 patients with specific infection were included, and MDR pathogens were identified in 23 patients with clinical infection (Fig. 1). The baseline demographic and clinical characteristics of the patients are shown in Table 1. No significant difference was found in age, gender, or etiology of SAP between the two groups. Hyperlipidemia was the leading cause of SAP in our study. Bacteremia was present among 11 in the MDR group and one in the non-MDR group (P=0.0002). Ten patients with positive blood cultures in the MDR group were died. Neither polymicrobial infection nor concomitant fungal infection incidence has significant difference between the two groups. Sixteen patients (69.6%) received antibiotics on admission for prophylaxis in the MDR group and 19 patients (67.9%) in the non-MDR group. More patients in MDR group underwent open necrosectomy than in non-MDR group (12 patients vs. 2 patients). In both groups, the rate of receiving enteral nutrition support was significantly higher than that in parenteral

FIG. 1. Inclusion and classification of the study patients. SAP indicates severe acute pancreatitis; MDR, multidrug resistant.
The mean duration of hospital stay was longer in the patients with MDR pathogen infections ($P = 0.0135$). The hospitalization expenses of MDR group were much higher than that in non-MDR group (22844.54 vs. 7900.62, $P = 0.039$). The overall mortality among these patients was 41.1% (21 out of 51 patients) and the mortality of MDR group was higher than that in non-MDR group (56.5% vs. 28.6%, $P = 0.0436$) (Table 1).

In total, 69 bacterial (97.2%) and two fungal (2.8%) pathogens were detected in 51 patients. The microorganisms are summarized in Table 2. Our data indicated that gram-negative isolates (63.8%) were commonly identified in SAP patients. Acinetobacter baumannii (A baumannii) (18.8%) and Enterococcus species (15.9%) were mainly identified and followed by Klebsiella pneumoniae (13.0%). MDR pathogens were confirmed in 39 episodes, of which 25 (64.1%) were gram-negative bacteria and 14 (35.9%) were gram-positive bacteria. The top two MDR pathogens were $A$ baumannii ($n = 9$) and Enterococcus species ($n = 7$). Thirty-nine MDR isolates were examined in 23 patients, including four specimens from surgical drainage, one from percutaneous drainage, 18 from blood specimens, and 16 specimens from pus.

### Table 1. Comparison of demographics and clinical characteristics between MDR and non-MDR groups

| Characteristics               | MDR $n = 23$ | Non-MDR $n = 28$ | $P$ value |
|-------------------------------|--------------|------------------|-----------|
| Gender                        |              |                  | 0.279     |
| Male                          | 14           | 21               |           |
| Female                        | 9            | 7                |           |
| Age                           | 44.82 ± 14.51| 45.68 ± 14.03    | 0.833     |
| Etiology, n (%)               |              |                  | 0.9023    |
| Biliary                       | 7 (30.5)     | 9 (32.1)         |           |
| Hyperlipidemia                | 13 (56.5)    | 17 (60.7)        |           |
| Alcohol-related               | 1 (4.3)      | 1 (3.6)          |           |
| Other                         | 2 (8.7)      | 1 (3.6)          |           |
| Bacteremia                    | 11           | 1                |           |
| Mortality (%)                 | 13           | 8                |           |
| Fungal infection              | 2            | 0                |           |
| Polymicrobial infection       | 7            | 1                |           |
| ICU admission                 | 16           | 21               |           |
| Application of antibiotics, n (%) | 0.899     |                  |           |
| Prophylaxis (on admission)    | 16 (69.6%)   | 19 (67.9%)       |           |
| Treatment (on admission)      | 7 (30.4%)    | 9 (32.1%)        |           |
| Nutrition support, n (%)      |              |                  | 0.934     |
| Enteral nutrition             | 19 (82.6%)   | 24 (85.7%)       |           |
| Parenteral nutrition          | 4 (17.4%)    | 4 (14.3%)        |           |
| Duration of antibiotics (days)| 19 (7-29)    | 10 (4.5-12.5)    |           |
| Hospital stay                 | 27.39 ± 20.54| 15.12 ± 9.83     |           |
| Hospitalization costs (dollar)| 22844.54 (9249.72–39555.76) | 7900.62 (3408.51–13391.07) | 0.039* |

$*P < 0.05$.

MDR indicates multidrug resistant.

### Table 2. Total microorganisms and multidrug resistant microorganisms in 51 patients

| Total microorganisms     | Isolates, no. (%) |
|--------------------------|-------------------|
| Isolated gram-positive bacteria |               |
| Staphylococcus aureus     | 22 (31.9)         |
| Enterococci species      | 11 (15.9)         |
| Coagulase-negative staphylococci | 5 (7.3)     |
| Others                   | 5 (8.8)           |
| Isolated gram-negative bacteria | 44 (63.8) |
| Acinetobacter baumanni   | 13 (18.8)         |
| Klebsiella pneumonia     | 9 (13.0)          |
| Escherichia coli         | 7 (10.2)          |
| Burkholderia cepacia     | 5 (7.3)           |
| Enterobacter cloacae     | 6 (8.7)           |
| Pseudomonas aeruginosa   | 1 (1.4)           |
| Others                   | 3 (4.4)           |
| Fungus                   | 3 (4.3)           |
| Candida albicans         | 2 (2.9)           |
| Candida glabrata         | 1 (1.4)           |
| MDR bacteria             | N = 39            |
| Isolated gram-positive bacteria | 14 (35.9) |
| Staphylococcus aureus     | 1 (2.6)           |
| Enterococci species      | 7 (17.9)          |
| Coagulase-negative staphylococci | 3 (7.7)     |
| Others                   | 3 (7.7)           |
| Isolated gram-negative bacteria | 25 (64.1) |
| Acinetobacter baumanni   | 9 (23.1)          |
| Klebsiella pneumonia     | 5 (12.8)          |
| Escherichia coli         | 4 (10.2)          |
| Burkholderia cepacia     | 1 (2.6)           |
| Enterobacter cloacae     | 4 (10.3)          |
| Serratia marcescens      | 2 (5.1)           |

### MDR pathogen infection

In total, 69 bacterial (97.2%) and two fungal (2.8%) pathogens were detected in 51 patients. The microorganisms are summarized in Table 2. Our data indicated that gram-negative isolates (63.8%) were commonly identified in SAP patients. Acinetobacter baumanni (A baumanni) (18.8%) and Enterococcus species (15.9%) were mainly identified and followed by Klebsiella pneumoniae (13.0%). MDR pathogens were confirmed in 39 episodes, of which 25 (64.1%) were gram-negative bacteria and 14 (35.9%) were gram-positive bacteria. The top two MDR pathogens were $A$ baumanni ($n = 9$) and Enterococcus species ($n = 7$). Thirty-nine MDR isolates were examined in 23 patients, including four specimens from surgical drainage, one from percutaneous drainage, 18 from blood specimens, and 16 specimens from pus.

### Risk factor analysis of MDR pathogen infection

The relationship between MDR pathogens and potential risk factors was screened by correlation analysis, and the results are presented in Table 3. Our data suggested that there was no difference in invasive procedures, recently received antibiotics treatments, transferred from other institution, and ICU admission between the two groups ($P<0.05$), and systemic disease.
Table 3. Correlation analysis between MDR pathogen infection and potential risk factors.

| Risk factors                              | C   | P value |
|-------------------------------------------|-----|---------|
| Systemic disease                          | 0.3295 | 0.014* |
| Invasive procedures                       | 0.2303 | 0.104  |
| Open necrosectomy                         | 0.5241 | 0.0002*|
| Recently received antibiotics treatments   | 0.0035 | 0.981  |
| Transferred                               | 0.0898 | 0.525  |
| ICU admission                             | 0.0817 | 0.564  |
| Initial use of carbapenem                 | 0.2835 | 0.044* |

*P < 0.05.

MDR indicates multidrug resistant.

(P = 0.0136), initial use of carbapenem (P = 0.0438), and open necrosectomy (P = 0.0002) were the risk factors for MDR pathogen infection in SAP. To further explore the independent risk factor of MDR pathogen infection, the logistic analysis was performed. The multivariable analysis revealed that surgical intervention was the independent risk factor for MDR in SAP patients (OR: 15.6, 95%, 95% CI: 2.951–82.469, P = 0.0012) (Table 4).

**DISCUSSION**

Previous studies showed that cholelithiasis was the most common etiological factors for MDR resistance in China (19,20). In our study, hyperlipidemia (n = 30, 58.9%) was the primary etiology, which was different from the studies performed in other regions and countries (21,22). The cold climate and unhealthy lifestyle such as high-fat diet and deficiency of movement result in higher incidence of hyperlipidemia pancreatitis in the northeast of China. Despite that, several studies have documented a shift from gram-negative to gram-positive isolates, and we found that the gram-negative pathogens were the dominating bacteria in SAP (23–25). Our data was consistent with the previous studies. The cultured *Enterococci* species were generally sensitive to vancomycin (only one isolate showed vancomycin resistant) compared with other studies (26–28). *A baumannii* was the main MDR pathogen in our study, and there are several explanations for its higher incidence. Prior antibiotic use was the most important risk factor for the acquisition of MDR *A baumannii* (29). Carbapenems, third-generation cephalosporins, and/or fluoroquinolones are the independent risk factors for the acquisition of MDR *A baumannii* (30,31). In this study, we observed that the above-mentioned antibiotics were used either for prophylactic or therapeutic purpose in all patients. Third-generation cephalosporins and/or fluoroquinolones were intravenously used for either prophylactic or therapeutic purpose, although antibiotic prophylaxis is not recommended for the prevention of infective complications in AP (32,33). Carbapenem was considered a first-line treatment for patients who were suspected with infected pancreatic necrosis, and the clinical symptoms were obvious. In addition, conventional treatments of SAP, including mechanical ventilation and nasogastric tube use, may result in *A baumannii* infection (34). Besides, 16 out of 23 patients were admitted to ICU, which may improve the high rate of MDR *A baumannii*. MDR pathogens may be caused by unrestricted antibiotic use (35–37). Adequate antibiotic therapy including optimal dosage has a significant impact on clinical outcome in patients with life-threatening infections such as those occurring in SAP patients. Inappropriate antibiotics dose and duration lead to MDR pathogens. SAP can also affect the pharmacokinetics of antibiotics. He et al. (38) found that plasma trough concentration of vancomycin was significantly reduced in SAP patients. The most probable cause was that SAP-related SIRS affected the distribution and excretion of vancomycin. Higher dosage regimens (exceed instruction recommended dosage) are needed to enhance the clinical effect and avoid MDR pathogen. Thus, surgeons should use antibiotics appropriately at the next stage to avoid over-prescription.

Our data suggested a strong correlation between MDR pathogen and systemic disease, initial use of carbapenem and open necrosectomy. Further data showed that open necrosectomy was the independent risk factor for producing MDR. van Santvoort et al. (39,40) found that the step-up approach for SAP was superior to open necrosectomy because of its relatively lower incidence of postoperative complications and long-term pancreatic function deficiency. In our study, the step-up approach (percutaneous catheter drainage (PCD) would be performed initially) was first carried out, and open necrosectomy was then selectively performed for patients who cannot be treated via PCD 4 weeks after the onset of pancreatitis (41). However, the over enthusiasm for PCD might yield the SAP patient a longer use of broad-spectrum antibiotics, which may delay the open necrosectomy time, damage the microbial ecology, and produce MDR pathogen. In addition, open necrosectomy brought more therapeutic interventions, such as peritoneal cavity drainage tube and usage of suctioning equipment. These may increase the incidence of MDR pathogen. Our data suggested that the hospital stay was longer, and hospitalization expenses and mortality were much higher in patients who had MDR pathogen infections. Thus, preventing the production of MDR and improving SAP patient outcome are the issues for further study. The multidisciplinary team (MDT) has shown to ameliorate the outcomes of various diseases (42,43). MDT management may probably provide practical recommendations and prevent MDR pathogen production in SAP patients.

There were some limitations in our study. First, this study was a retrospective analysis, and the samples size was limited.

| Characteristic | β     | SE  | Waldχ2 | P     | OR   | 95% CI     |
|---------------|-------|-----|--------|-------|------|------------|
| Open necrosectomy | 2.747 | 0.850 | 10.457 | 0.001* | 15.600 | 2.951–82.469 |

*P < 0.05.

MDR indicates multidrug resistant.
(116 patients met the criteria for SAP while only 51 patients were included). Second, the results were derived from a single-center experience in the northeast of China which could not be generalized to other hospitals. Third, the empirical treatment for SAP patients was different and hence yielded different results, including therapeutic strategies (PCD or PCD plus open necrosectomy), nutrition support method (i.e., enteral nutrition and parenteral nutrition), and the use of equipment (i.e., nasoenteric tube placement). Moreover, several studies have demonstrated that selective decontamination may decrease the complications and reduce the mortality in SAP (44.45). In our study, selective decontamination, which could influence the ratio of MDR organisms and the mortality of SAP patients, was avoided.

**CONCLUSION**

In summary, MDR pathogen infections were common in SAP patients and gram-negative bacteria were the major pathogen. Systemic disease, initial use of carbapenem, and surgical intervention were the risk factors for MDR pathogen infections in SAP. Furthermore, surgical intervention was the independent risk factor for the infection of MDR pathogen. Clinicians should be aware of the high incidence of MDR pathogen infections, and accurate use of antibiotics could prevent MDR pathogen infections.

**ACKNOWLEDGMENT**

The authors thank Professor Bei Sun from the Department of Pancreatic and Biliary Surgery of The First Affiliated Hospital to Harbin Medical University for the use of their facilities and collaboration.

**REFERENCES**

1. Freeman ML, Werner J, van Santvoort HC, Baron TH, Besselink MG, Wendler JA, Horvath KD, vanSonnenberg E, Bollen TL, Vege SS: International Multi-disciplinary Panel of Speakers and Moderators: interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. *Pancreas* 41(8):1176–1194, 2012.

2. Petrov MS, ShaabanBG, Chakraborty M, Phillips AR, Wendler JA: Organ failure and infection of necrotic pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. *Gastroenterology* 139(3):813–820, 2010.

3. Mikhailovic A, Pindak D, Daniel I, Pechan J: Septic complications of acute pancreatitis. *Bratisl Lek Listy* 107(8):296–313, 2006.

4. Cully M: Public health: the politics of antibiotics. *Nature* 509(7498):S16–S17, 2014.

5. De Waele JJ, Vogelaers D, Hoste E, Blot S, Colardyn F: Emergence of antibiotic resistance in infected pancreatic necrosis. *Arch Surg* 139(12):1371–1375, 2004.

6. Moka P, Goswami P, Kapil A, Xess I, Sreenivas V, Saraya A: Impact of antibiotic-resistant bacterial and fungal infections in outcome of acute pancreatitis. *Pancreas* 47(4):489–494, 2018.

7. Khare V, Gupta P, Haider F, Begum R: Study on MICs of Tigecycline in clinical isolates of carbapenem resistant enterobacteriaceae (CRE) at a tertiary care centre in north India. *J Clin Diagn Res* 11(12):DC18–DC21, 2017.

8. Sanden L, Paul M, Leibovici I, Andreaassen S: Quantifying the associations between antibiotics exposure and resistance—a step towards personalised antibiograms. * Eur J Clin Microbiol Infect Dis* 35(12):1989–1996, 2016.

9. Brusselaers N, Vogelaers D, Blot S: The rising problem of antimicrobial resistance in the intensive care unit. *Ann Intensive Care* 1:47, 2011.

10. Huang X, Deng ZD, Yin YL, Deng M, Hu BJ, Li LY, Li JB, Zhou BP, Wang XG, Zong ZY, et al.: Chinese experts’ consensus on prevention and control of multidrug resistance infection in healthcare-associated infection. *Clin Infect Control* 14(1):1–8, 2015.

11. Milovanovic T, Dumić I, Velčić-Kovac: Epidemiology and risk factors for multidrug-resistant hospital-acquired urinary tract infection in patients with liver cirrhosis: single centre experience in Serbia. *BMC Infect Dis* 19(1):141, 2019.

12. Song JU, Park HK, Kang HK, Lee J: Proposed risk factors for infection with multidrug-resistant pathogens in hemodialysis patients hospitalized with pneumonia. *BMC Infect Dis* 17(1):681, 2017.

13. Lee HS, Lee SK, Park DH, Lee SS, Seo DW, Kim MH, Chong YP: Emergence of multidrug resistant infection in patients with severe acute pancreatitis. *Pancreatology* 14(6):450–453, 2014.

14. Banks PA, Bolten TL, Devenish C, Goossen HG, Johnson CD, Sar M, Tsios GC, Vege SS: Acute Pancreatitis Classification Working Group: Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 62(1):102–111, 2013.

15. Tenner S, Baille J, DeWitt J, Vege SS: American College of Gastroenterology: American College of Gastroenterology Guidelines: management of acute pancreatitis. *Am J Gastroenterol* 108(9):1400–1415, 2013.

16. Clinical Practice Guidelines Standards. *Institute M100-S22 Performance standards for antimicrobial susceptibility testing: twenty second international supplement.* *Wayne PA: CLSI*, 2012.

17. Aguiar EB, Maciel LC, Halpern M, de Lemos AS, Ferreira AL, Basta ST, Gonçalves RT, de Gouveia EF, Santoro-Lopes G: Outcome of bacteremia caused by extended-spectrum beta-lactamase-producing enterobacteriaceae after solid organ transplantation. *Transplant Proc* 46(6):1753–1756, 2014.

18. Magirorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al.: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 18(3):268–281, 2012.

19. Zhu Y, Pan X, Zeng H, He W, Xia L, Liu F, ZHU Y, Chen Y, LV N: A study on the etiology, severity, and mortality of 3260 patients with acute pancreatitis according to the revised Atlanta classification in Jiangsu, China over an 8-year period. *Pancreas* 46(4):504–509, 2017.

20. Zheng Y, Zhou Z, LI H, LI J, JI A, MA B, Zhang T, Liao Q, YE Y, Zhang Z, et al.: A multicenter study on etiology of acute pancreatitis in Beijing during 5 years. *Pancreas* 44(3):409–414, 2015.

21. Sakorafas GH, Tsiontou AG: Etiology and pathogenesis of acute pancreatitis: current concepts. *J Clin Gastroenterol* 30(4):343–356, 2000.

22. Vidasdottir H, Møller PH, Vidasdottir H, Thorarinsdottir H, Bjorssen ES: Acute pancreatitis: a prospective study on incidence, etiology, and outcome. *Eur J Gastroenterol Hepatol* 25(9):1068–1075, 2013.

23. Su MS, Lin MH, Zhao QH, Liu ZW, HE L, JIA N: Clinical study of distribution and drug resistance of pathogens in patients with severe acute pancreatitis. *Clin Med (Eng)* 125(10):1772–1776, 2012.

24. Gloor B, Müller CA, Worni M, Stahel PF, Redaelli C, Uhli W, Büchner MW: Pancreatic infection in severe pancreatitis: the role of fungus and multiresistant organisms. *Arch Surg* 136(5):592–596, 2001.

25. Büchner MW, Gloor B, Müller CA, Friess H, Seiler CA, Uhli W: Acute necrotizing pancreatitis: treatment strategy according to the status of infection. *Ann Surg 232(5):619–626, 2000.

26. Noor MT, Radhakrishna Y, Kockar R, Ray P, Wij JD, Sinha SK, Singh K: Bacteriology of infection in severe acute pancreatitis. *JOP* 12(1):19–25, 2011.

27. Stepanov W, B, Michael H B, Paxton V D, BEN L Z: The microbiology of secondary and postoperative pancreatic infections: implications for antimicrobial management. *Arch Surg* 146(5):613–619, 2011.

28. Howard TJ, Temple MB: Prophylactic antibiotics after the bacteriology of infected necrosis in severe acute pancreatitis. *Am J Surg* 195:759–767, 2002.

29. Falagas ME, Kopterides P: Risk factors for the isolation of multi-drug-resistant acinetobacter baumannii and pseudomonas aeruginosa: a systematic review of the literature. *J Hosp Infect* 64(1):7–15, 2006.

30. del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Linares P, Canle D, Molina F, Villanueva R, Cisneros JM, BOU G: Hospital outbreak caused by a carbapenem-resistant strain of acinetobacter baumannii: Patient prognosis and risk factors for colonisation and infection. *Clin Microbiol Infect* 11(7):540–546, 2005.

31. Neier S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M, Onimus T, Saulnier F, Mathieu D, Durocher A: First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. *Crit Care Med* 33(2):283–289, 2005.

32. Tenner S, Baille J, DeWitt J, Vege SS: American College of G: American college of gastroenterology guideline: management of acute pancreatitis. *Am J Gastroenterol* 108(9):1400–1415, 2013.

33. Yokoe M, Takada T, Mayumi T, Yoshida M, Isaji S, Wada K, Itoi T, Sata N, Gabata T, Igarashi H, et al.: Japanese guidelines for the management of acute pancreatitis: Japanese guidelines 2015. *J Hepatobiliary Pancreat Sci* 22(6):408–432, 2015.

34. Zhou HY, Yuan Z, Du YP: Prior use of four invasive procedures increases the risk of acinetobacter baumannii nosocomial bacteremia among patients in intensive care units: a systematic review and meta-analysis. *Int J Infect Dis* 22:25–30, 2014.
35. Kim SY, Jung JY, Kang YA, Lim JE, Kim EY, Lee SK, Park SC, Chung KS, Park BH, Kim YS, et al.: Risk factors for occurrence and 30-day mortality for carbapenem-resistant acetobacter baumannii bacteremia in an intensive care unit. J Korean Med Sci 27(8):939–947, 2012.

36. Jang TN, Lee SH, Huang CH, Lee CL, Chen WY: Risk factors and impact of nosocomial acetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control study. J Hosp Infect 73(2):143–150, 2009.

37. Jung JY, Park MS, Kim SE, Park BH, Son JY, Kim EY, Lim JE, Lee SK, Lee SH, Lee KJ, et al.: Risk factors for multi-drug resistant acetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis 10:228, 2010.

38. He J, Mao EQ, Feng J, Jiang HT, Yang WH, Chen EZ: The pharmacokinetics of vancomycin in patients with severe acute pancreatitis. Eur J Clin Pharmacol 72(6):697–702, 2016.

39. van Santvoort HC, Besselink MG, Bakker OJ, Hofker HS, Boerman MA, Dejong CH, van Goor H, Schaapherder AF, van Eijck CH, Bollen TL, et al.; Dutch Pancreatitis Study Group. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med 362(16):1491–1502, 2010.

40. Pannala R, Ross AS: Pancreatic endotherapy and necrosectomy. Curr Treat Options Gastroenterol 13(2):185–197, 2015.

41. Ji L, Wang G, Li L, Li YL, Hu JS, Zhang GQ, Chen HZ, Chen H, Kong R, Bai XW, et al.: Risk factors for the need of surgical necrosectomy after percutaneous catheter drainage in the management of infection secondary to necrotizing pancreatitis. Pancreas 47(4):436–443, 2018.

42. Chen Y, Guo C, Zhang Q, Shen Y, Li Y, Li X, Bai X, Liang T: Patients with pancreatic cystic neoplasms can benefit from management of multidisciplinary team: experience from a Chinese academic center. Panreatology 18(7):799–804, 2018.

43. Ricci C, Casadei R, Taffurelli G, Ingaldi C, D’Ambra M, Pacilio CA, Pagano N, Calulli L, Serra C, Santini D, et al.: The usefulness of a multidisciplinary team approach in decision making for pancreatic serous cystic neoplasms. JOP 15(6):577–580, 2014.

44. Sawa H, Urda T, Takeyama Y, Yasuda T, Shinzeki M, Matsumura N, Nakajima T, Matsumoto I, Fujita T, Ajiki T, et al.: Treatment outcome of selective digestive decontamination and enteral nutrition in patients with severe acute pancreatitis. J Hepatobiliary Pancreat Surg 14(5):503–508, 2007.

45. Kitamura N, Hiraoka T, Moriguchi T, Hirasawa H, Ohtani S: Efficacy of selective digestive decontamination (SDD) for severe acute pancreatitis. Nihon Rinsho 62(11):2065–2073, 2004.